Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

31,203 trials

NCT06447974
Recruiting
The Barts Charity Children's Environmental Health Clinic
Not applicable · United Kingdom · 2 sites
Registry update: 13 Aug 2026
NCT07128797
Recruiting
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）
Phase 1 · China · 5 sites
Registry update: 19 Aug 2025
NCT07629375
Recruiting
Standardization of a Platform of Preclinical Models Derived From NSCLC Patients
Not applicable · Italy · 1 site
Registry update: 5 Jun 2026
NCT06661655
Recruiting
Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients
Not applicable · France · 3 sites
Registry update: 15 Aug 2025
NCT07138560
Recruiting
BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease
Phase 4 · United States · 1 site
Registry update: 15 Oct 2026
NCT07203404
Recruiting
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
Early phase 1 · China · 1 site
Registry update: 3 Aug 2026
NCT06805890
Recruiting
Study of Tissue Repair in Inflammatory Bowel Disease Exploiting Organoid Technology
Not applicable · France · 1 site
Registry update: 21 Sept 2026
NCT07044687
Recruiting
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
Phase 4 · India · 14 sites
Registry update: 11 Sept 2026
NCT07217392
Recruiting
Left Bundle Branch Area Pacing (LBBAP) PMCF Study
Not applicable · United Arab Emirates, Brazil, Germany, Spain, France, India, Italy, Malaysia, Singapore · 15 sites
Registry update: 25 Sept 2026
NCT06757634
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Phase 3 · Argentina, Australia, Belgium, Bulgaria, China, Czechia, Germany, Denmark, Spain, Finland, France, United Kingdom, Greece, Hungary, Italy, South Korea, Mexico, Malaysia, Poland, Portugal, Romania, Thailand, Taiwan, United States · 237 sites
Registry update: 9 Oct 2026
NCT07102745
Recruiting
HomeLink2: Reducing Posthospitalization Mortality Through Structured Home Care and Nutritional Support
Not applicable · South Africa · 1 site
Registry update: 22 Jul 2026
NCT07090759
Recruiting
To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment
Phase 3 · China · 1 site
Registry update: 23 Jan 2026
NCT07372820
Recruiting
METABolic Deterioration in HTX Determines Outcomes
Not applicable · Germany · 1 site
Registry update: 28 Jan 2026
NCT07489105
Recruiting
Forge AHEAD: Feasibility of Yoga to Improve Cognitive Function
Not applicable · United States · 1 site
Registry update: 25 Mar 2026
NCT07019155
Recruiting
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
Not applicable · United States · 1 site
Registry update: 16 Oct 2026
NCT07099391
Recruiting
A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
Phase 1/2 · United States · 7 sites
Registry update: 2 Nov 2026
NCT06918834
Recruiting
Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients
Phase 2 · China · 5 sites
Registry update: 12 Sept 2025
NCT07112170
Recruiting
Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma
Not applicable · Canada · 1 site
Registry update: 5 Mar 2026
NCT07190638
Recruiting
Comparison of Outcomes and Surgical Time Between Cortical and Medullary Suture vs. Medullary-Only Suture: Cortex Clinical Trial
Not applicable · Brazil · 2 sites
Registry update: 24 Sept 2025
2025-520743-33-00
Recruiting
Phase 1b/2 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, in combination with regorafenib and tislelizumab in patients with advanced/metastatic colorectal cancer
Phase 1/2 · Spain · 6 sites
Registry update: 14 Oct 2026

Ordered by registry start date. Freshness and sponsorship never change the order.